No current IOL gives every person the natural autofocus of a young eye. That is the real limitation. It does not mean every useful improvement must be balanced by an invented downside.
A specific lens can be better than the lens it was compared with for a specific task and show no clinically meaningful loss in the outcomes that were tested. TECNIS Eyhance versus its standard monofocal control is a good example: the clinical benefit at intermediate distance should not be weakened just because a balanced sentence looks safer.
What the natural lens does that an IOL does not
A young natural lens changes shape when you move your attention from the road to the dashboard and then to a phone. That autofocus is called accommodation. Most current IOLs are fixed optics, so they create useful vision at different distances by other means.
This is why the first question is not “Which lens is perfect?” It is “At which distances and in which lighting do I need to function without glasses?”
Different categories solve different parts of the problem
A monofocal IOL is usually targeted mainly for one distance. If that target is far, expect glasses for close work and often for a computer or other arm’s-length tasks. Individual monofocal models are not optically identical, so “monofocal” does not automatically mean the best result on every quality measure.
An enhanced monofocal keeps a monofocal-style distance strategy while adding some useful intermediate range. It should not be sold as reading vision, but a demonstrated intermediate benefit should be stated plainly when the comparison supports it.
EDOF means extended depth of focus: a longer zone of useful focus rather than one narrow point. The label describes an outcome category, not one universal optical design. Near vision, contrast and night symptoms therefore have to be checked for the exact model.
Multifocal and trifocal lenses aim to cover more of the near-to-far range. Diffractive models distribute light between focal ranges; this can greatly reduce glasses use, while their own trials often show more halos or starbursts than monofocal controls. The size of that benefit and the frequency or severity of symptoms differ by model and by how the study asked the question.
A benefit does not automatically mean something else gets worse
Optical design always changes something, but that sentence alone does not prove a clinically important loss. Bench measurements can reveal a difference in the lens; patient trials tell us whether that difference was detected in vision, symptoms or daily function. I keep those two levels separate.
So I do not start from “every lens has a downside” and then search for one. I start from the exact lens used for comparison, the visual task, the lighting and what the study measured. If a study shows a benefit and no clinically meaningful worsening in the measured outcomes, that is the conclusion. If a trial misses its own target—as the Vivity near-vision study did—that also belongs in the first page of the explanation.
Questions that make the choice concrete
- Which exact distance are we targeting in each eye?
- Which tasks should I expect to do comfortably without glasses—not merely read once on a chart?
- What did the exact model show against its control for contrast and night symptoms?
- Did its pivotal study meet the target it set before the study began?
- Which part of your recommendation comes from published evidence, and which part comes from your clinical experience with eyes like mine?
The surgeon still decides what is medically suitable for your cornea, retina, optic nerve and measurements. Your part is to make the visual priority specific enough that “good vision” has a real meaning.